Coming from a fairly large firm – Cubist Pharmaceuticals Inc. – before its $8.4bn acquisition by Merck & Co. Inc. in 2014, Morphic Therapeutic Inc. President and CEO Praveen Tipirneni said he expected more volatility working for the first time at a small start-up, "but it's been a pretty smooth ride."
Morphic launched in 2015 to develop oral small molecule integrin inhibitors based on the research of integrin discoverer Tim Springer...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?